Timothy Chan

Dec 2, 2024 | techinasia.com | Timothy Chan

Kelvin Low co-authored this article. There’s a new subject for debate in the blockchain world: asset tokenization. More specifically, the conversation is around whether asset tokenization – the process of turning the ownership rights in physical things into tradable digital tokens – actually does what it promises. One camp believes it does. A joint report co-authored by Liquefy, Sidley, KPMG, and Colliers claims the usual benefits: lowering barriers to entry, efficiency, transparency, and so on.

Jan 5, 2024 | mondaq.com | James Morris |Timothy Chan |Etelka Bogardi |Wilson Ang

In this latest episode of our EMEA regulatory insights series colleagues from Australia, Hong Kong, and Singapore provide their thoughts and insights on what 2024 holds from a financial services regulatory perspective. Australia - 0:00 Hong Kong - 14:25 Singapore - 24:16 Spotify/ Apple The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Dec 27, 2023 | regulationtomorrow.com | James Morris |Timothy Chan |Etelka Bogardi |Wilson Ang |James McGrath Morris |Simon Lovegrove

In this latest episode of our EMEA regulatory insights series colleagues from Australia, Hong Kong, and Singapore provide their thoughts and insights on what 2024 holds from a financial services regulatory perspective. The podcast can be found here.

Oct 25, 2023 | acsjournals.onlinelibrary.wiley.com | Guido Kroemer |Timothy Chan |Lorenzo Galluzzi

INTRODUCTION Until the beginning of the 21st century, cancer was largely viewed as a purely cell-intrinsic disease of genetic or epigenetic origin, implying that personalized treatment strategies were mostly focused on dissecting malignant cell features.1 However, cancer is a systemic disease that involves a progressive derailment of immunological, metabolic, neuroendocrine, and potentially microbial features, hence affecting the entire bodywide ecosystem.2, 3 This notion has been...

Jun 16, 2023 | nature.com | Timothy Chan

AbstractOver the past decade, the emergence of effective immunotherapies has revolutionized the clinical management of many types of cancers. However, long-term durable tumour control is only achieved in a fraction of patients who receive these therapies. Understanding the mechanisms underlying clinical response and resistance to treatment is therefore essential to expanding the level of clinical benefit obtained from immunotherapies.